Intelligence Feed event · Macro · 2026-10-01

    Theriva Biologics Publishes Phase 2b VIRAGE Pancreatic Cancer Data in Nature Medicine

    Question

    Theriva Biologics Publishes Phase 2b VIRAGE Pancreatic Cancer Data in Nature Medicine

    Direct answer

    Theriva Biologics announced that Nature Medicine published full results from the Phase 2b VIRAGE clinical trial, showing that its oncolytic adenovirus candidate VCN-01 paired with standard chemotherapy achieved improved progression-free survival and overall survival in metastatic pancreatic cancer. The publication provides peer-reviewed validation for the mechanism of action, supporting prospective Phase 3 clinical development and regulatory partnering discussions.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Theriva Biologics Publishes Phase 2b VIRAGE Pancreatic Cancer Data in Nature Medicine”, revision 1, evidence through 2026-10-01. https://marketontology.com/market-events/2026-10-01/theriva-biologics-publishes-phase-2b-virage-pancreatic-cancer-data-in-nature-med-0e1861

    MACRO
    Theriva Biologics Publishes Phase 2b VIRAGE Pancreatic Cancer Data in Nature Medicine
    Theriva Biologics announced that Nature Medicine published full results from the Phase 2b VIRAGE clinical trial, showing that its oncolytic adenovirus candidate VCN-01 paired with standard chemotherapy achieved improved progression-free survival and overall survival in metastatic pancreatic cancer. The publication provides peer-reviewed validation for the mechanism of action, supporting prospective Phase 3 clinical development and regulatory partnering discussions.
    TOVX
    Impact
    65
    OCT 1
    SIG
    85%
    TOVX
    Theriva Biologics Publishes Phase 2b VIRAGE Pancreatic Cancer Data in Nature Medicine
    Theriva Biologics announced that Nature Medicine published full results from the Phase 2b VIRAGE clinical trial, showing that its oncolytic adenovirus candidate VCN-01 paired with standard chemotherapy achieved improved progression-free survival and overall survival in metastatic pancreatic cancer. The publication provides peer-reviewed validation for the mechanism of action, supporting prospective Phase 3 clinical development and regulatory partnering discussions.
    → Peer-reviewed Phase 2b survival efficacy validation increases the net present value of TOVX's VCN-01 pipeline assets.
    Impact
    Theriva Biologics announced that Nature Medicine published full results from the Phase 2b VIRAGE clinical trial, showing that its oncolytic adenovirus candidate VCN-01 paired with standard chemotherapy achieved improved progression-free survival and overall survival in metastatic pancreatic cancer. The publication provides peer-reviewed validation for the mechanism of action, supporting prospective Phase 3 clinical development and regulatory partnering discussions.
    Affected
    TOVX
    Transmission
    Peer-reviewed Phase 2b survival efficacy validation increases the net present value of TOVX's VCN-01 pipeline assets.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    TOVXbiotech pipeline derisking via peer-reviewed Phase 2b publicationUp1-5dTheriva Biologics announced the publication of Phase 2b VIRAGE trial results in Nature Medicine.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month